The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia - PubMed (original) (raw)
doi: 10.1038/leu.2010.267. Epub 2010 Nov 16.
W-C Lei, B-S Ko, H-A Hou, C-Y Chen, J-L Tang, M Yao, W Tsay, S-J Wu, S-Y Huang, S-C Hsu, Y-C Chen, Y-C Chang, K-T Kuo, F-Y Lee, M-C Liu, C-W Liu, M-H Tseng, C-F Huang, H-F Tien
Affiliations
- PMID: 21079611
- DOI: 10.1038/leu.2010.267
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
W-C Chou et al. Leukemia. 2011 Feb.
Abstract
Although the clinical features of the Isocitrate dehydrogenase 2 (IDH2) mutation in acute myeloid leukemia (AML) have been characterized, its prognostic significance remains controversial and its stability has not been investigated. We analyzed 446 adults with primary non-M3 AML and found IDH2 R172, R140 and IDH1 R132 mutations occurred at a frequency of 2.9, 9.2 and 6.1%, respectively. Compared with wild-type IDH2, mutation of IDH2 was associated with higher platelet counts, intermediate-risk or normal karyotype and isolated +8, but was inversely correlated with expression of HLA-DR, CD34, CD15, CD7 and CD56, and was mutually exclusive with WT1 mutation and chromosomal translocations involving core-binding factors. All these correlations became stronger when IDH1 and IDH2 mutations were considered together. Multivariate analysis revealed IDH2 mutation as an independent favorable prognostic factor. IDH2(-)/FLT3-ITD(+) genotype conferred especially negative impact on survival. Compared with IDH2 R140 mutation, IDH2 R172 mutation was associated with younger age, lower white blood cell count and lactate dehydrogenase level, and was mutually exclusive with NPM1 mutation. Serial analyses of IDH2 mutations at both diagnosis and relapse in 121 patients confirmed high stability of IDH2 mutations. In conclusion, IDH2 mutation is a stable marker during disease evolution and confers favorable prognosis.
Similar articles
- IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. Paschka P, et al. J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567020 - IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Marcucci G, et al. J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368543 Free PMC article. - The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, Gale RE. Green CL, et al. Blood. 2011 Jul 14;118(2):409-12. doi: 10.1182/blood-2010-12-322479. Epub 2011 May 19. Blood. 2011. PMID: 21596855 - IDH mutations in acute myeloid leukemia.
Rakheja D, Konoplev S, Medeiros LJ, Chen W. Rakheja D, et al. Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Hum Pathol. 2012. PMID: 22917530 Review. - Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Medeiros BC, et al. Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Leukemia. 2017. PMID: 27721426 Free PMC article. Review.
Cited by
- IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H, Ye D, Guan KL, Xiong Y. Yang H, et al. Clin Cancer Res. 2012 Oct 15;18(20):5562-71. doi: 10.1158/1078-0432.CCR-12-1773. Clin Cancer Res. 2012. PMID: 23071358 Free PMC article. Review. - Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults.
Cheng CL, Li CC, Hou HA, Fang WQ, Chang CH, Lin CT, Tang JL, Chou WC, Chen CY, Yao M, Huang SY, Ko BS, Wu SJ, Tsay W, Tien HF. Cheng CL, et al. BMC Cancer. 2015 May 2;15:344. doi: 10.1186/s12885-015-1376-9. BMC Cancer. 2015. PMID: 25934556 Free PMC article. - The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients.
Park MN. Park MN. Int J Mol Sci. 2023 Jul 27;24(15):12037. doi: 10.3390/ijms241512037. Int J Mol Sci. 2023. PMID: 37569414 Free PMC article. Review. - Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM, Majeti R. Chan SM, et al. Int J Hematol. 2013 Dec;98(6):648-57. doi: 10.1007/s12185-013-1407-8. Epub 2013 Aug 15. Int J Hematol. 2013. PMID: 23949914 Free PMC article. Review. - The epigenetic landscape of acute myeloid leukemia.
Conway O'Brien E, Prideaux S, Chevassut T. Conway O'Brien E, et al. Adv Hematol. 2014;2014:103175. doi: 10.1155/2014/103175. Epub 2014 Mar 23. Adv Hematol. 2014. PMID: 24778653 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous